




PHARMACEUTICAL 2021

Aravive Inc.
Rank 177 of 402





PHARMACEUTICAL 2021

Aravive Inc.
Rank 177 of 402



The relative strengths and weaknesses of Aravive Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aravive Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 49% points. The greatest weakness of Aravive Inc. is the variable Intangible Assets, reducing the Economic Capital Ratio by 10% points.

The company's Economic Capital Ratio, given in the ranking table, is 119%, being 72% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	61,689
Cost of Goods Sold	0
Intangible Assets	97
Liabilities, Current	9,461
Liabilities, Non-Current	6,431
Other Assets	5,398
Other Compr. Net Income	0
Other Expenses	5,784
Other Liabilities	3,763
Other Net Income	241
Other Revenues	5,685
Property and Equipment	526
Research and Development	17,620
Selling, General and Administrative Expense	13,065

Output Variable	Value in 1000 USD
Assets	67,710
Liabilities	19,655
Expenses	36,469
Revenues	5,685
Stockholders Equity	48,055
Net Income	-30,543
Comprehensive Net Income	-30,543
Economic Capital Ratio	119%